Global Thalassemia Market Report: 2016 Edition - New Report by Koncept Analytics

1
Global Thalassemia Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details

• Executive Summary
• Thalassemia is a hereditary blood disorder in
  which a persons body makes an abnormal form of
  hemoglobin, which is the protein molecule in red
  blood cells (RBCs), which carries oxygen. The
  disorder results in unwarranted damage of red
  blood cells, which leads to anemia. Anemia is a
  condition in which the body doesnt have adequate
  amount of normal and healthy red blood cells.
  There are majorly two types of thalassemia based
  on these proteins known as the Alpha thalassemia
  and the Beta thalassemia. There is also a third
  type viz. Sickle beta thalassemia, which is like
  a combination of sickle cell disease and beta
  thalassemia.
• Even though it is a rare genetic disorder, the
  number of people affected by it has been growing
  with time. While those with thalassemia minor
  have hardly any threat to their life and only
  require occasional blood transfusion to sustain,
  thalassemia major patients need to go for
  periodic transfusions for a sustained life. In
  case of infants, thalassemia major often leads to
  still birth or cause death shortly after the
  babys birth. Presently the only cure for
  thalassemia is a bone marrow transplantation
  therapy, which is done mostly for severe cases of
  thalassemia.
• The key factors which are anticipated to drive
  this market include rising healthcare
  expenditure, rising spending on stem cell therapy
  research and development and rising population in
  the East-Asia and Pacific region of the world.
  Some of the noteworthy progresses of this
  industry include the advances in the iron
  chelation therapy, development of gene therapy
  and fetal hemoglobin inducers as potential
  curatives for thalassemia. However, the growth of
  respective industry is challenged by the high
  cost of treatments, lack of alternative
  treatments and unmet market of the Asia-Pacific.
• The report provides a comprehensive study of
  global thalassemia market and also major regional
  markets. Furthermore, market dynamics such as key
  trends and development and challenges are
  analyzed in depth. The global thalassemia
  industry is highly competitive consisting of
  several companies including the Lonza group,
  Acceleron Pharma, BlueBird Bio and Sangamo
  Biosciences etc. The competitive landscape of the
  respective market, along with the company
  profiles of the leading players are also
  discussed in detail.

3
Bone marrow transplantation is presently the only
chief cure for thalassemia major patients or
patients with transfusion-dependent thalassemia
Global Thalassemia Diagnosis by Category (2015E)

• It is noted that out of the total people
  suffering from severe thalassemia, only xx cases
  are estimated to be diagnosed with thalassemia
  major non-ß0/ß0 type, while xx cases are
  diagnosed with phenotypical ß0/ß0 type of
  thalassemia.
• It is estimated that in the year 2015, nearly
  xx.xx of the global transfusion-dependent ß
  thalassemia patients were from the Middle-East
  region and xx.x were from the South-East Asian
  region.
• The global bone marrow transplant therapy revenue
  is estimated to be USxx.xx billion for the year
  2015. It is estimated to grow at a CAGR of xx
  over the next five years and is forecasted to
  reach USxxx by the end of the year 2020.

Global Transfusion-Dependent ß Thalassemia by
Region (2015E)
Global Bone Marrow Transplant Revenue
(2015E-2020F)
4
Transfusion-dependent patients are those whose
level of severity of disease is so high that
regular blood transfusions have to be conducted
for a sustained life and healthy functioning of
these patients.
The US ß Thalassemia Carrier Patients Forecast
(2016F-2020F)

• The number of beta thalassemia carriers in the US
  is estimated to have reached . thousand in the
  year 2015. The number is expected to grow further
  in the future years, and is forecasted to grow at
  a CAGR of xx over the period 2016-2020
• The number of beta thalassemia major patients for
  the year 2014 in the US is noted to be xx.x
  thousand and is estimated to have reached xx
  thousand in the year 2015, marking a slight
  growth of xx.
• It is forecasted that the number of
  transfusion-dependent ß thalassemia patients in
  the US will rise gradually over time, reaching a
  total of xx thousand patients by the end of the
  year 2020.

The US Transfusion-Dependent ß Thalassemia
Patients (2016F-2020F)
The US ß Thalassemia Major Patients Forecast
(2016F-2020F)
5
The most effective type and also the most hard to
find is the sibling-matched bone marrow
transplant.
The US ß Thalassemia Sibling-Matched Stem Cell
Transplant (2016F-2020F)

• It is forecasted that the number of patients
  taking sibling-matched stem cell transplant among
  ß thalassemia patients in the US will reach a sum
  of xx0 thousand persons by the year 2020.
• It is forecasted that the number of
  transfusion-dependent ß thalassemia patients in
  the Europe will increase further at a CAGR of xx
  over the period 2016-2020, thereby reaching a sum
  of xxx thousand patients by the end of the year
  2020.
• Out of the total number of transfusion-dependent
  ß thalassemia patients in the Europe, it is
  estimated that nearly xxx thousand patients are
  those with major/intermediate level of severity,
  in the year 2015.

Europe Transfusion-Dependent ß Thalassemia Major
Patients
Europe Transfusion-Dependent ß Thalassemia
Patients
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Thalassemia Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com